Global Angiosarcoma Treatment Market - 2023-2030

Global Angiosarcoma Treatment Market - 2023-2030

Global Angiosarcoma Treatment Market reached US$ 253.1 million in 2022 and is expected to reach US$ 412.3 million by 2030 growing with a CAGR of 6.4% during the forecast period 2023-2030.

Angiosarcoma can develop anywhere in the body but most often occur in the skin, breast, liver, and spleen. The global angiosarcoma treatment market has witnessed significant growth in recent years due to the adoption of targeted therapies. For instance, vascular endothelial growth factor which is regulated in angiosarcoma can be targeted by tyrosine kinase inhibitors such as pazopanib and regorafenib.

Furthermore, significant growth drivers such as increasing clinical trials, increasing collaborations, and research and developments give rise to future market growth. Due to the massive rise in technological advancements in countries like the U.S. and Canada, the market is experiencing a rise in demand from North American regions. Significant key players like Amgen Inc., Eli Lilly, and Company, Genentech Inc., and others are actively operating in the market.

Dynamics

Increasing Research and Developments for Angiosarcoma Treatment

The global angiosarcoma treatment market has witnessed significant growth due to various recent research and developments. Angiosarcoma is usually diagnosed on the basis of medical history and clinical and imaging findings. Also, advanced research and developments in treating angiosarcoma help to accelerate market growth.

For instance, according an article entitled Cutaneous angiosarcoma treated with taxane-based chemoradiotherapy published on November 2022 states that clinical studies have suggested the importance of taxane-derived agents such as paclitaxel and docetaxel as first-line chemotherapy for treatment of cutaneous angiosarcoma. In addition, chemoradiotherapy with taxanes achieved a high response rate with significant improvement in overall survival compared with surgery or radiotherapy. Thus, the above factors help to boost the market growth in the forecast period.

Rising Technological Advancements for Angiosarcoma Treatment

Angiosarcoma develops in the inner lining of blood vessels and lymph vessels and the major advancements from major companies help to drive market growth. Skin is the most affected area with approximately 57.21% of cases being cutaneous angiosarcoma. These effective advancements help to transform research discoveries into new treatments and improve care for billions of people with angiosarcoma.

For instance, Springer Journal published an article in April 2023, states that spatial transcriptomics reveals topological immune landscapes of Asian head and neck angiosarcoma. It involves spatial transcriptomic profiling using the 10x Genomics Visium platform that is performed on representative cases characterized by the presence or absence of UV signatures and HHV-7 by revealing the topological tumor immune landscape of angiosarcoma. Thus, owing to the above factors the market is expected to boost over the forecast period.

Complications Associated with Lymphangiosarcoma is Expected to Hamper Global Market Growth

Complications of lymphangiosarcoma include cellulitis, musculoskeletal pain, psychological stress, and an increased risk of malignancy. Cellulitis usually occurs with oral antibiotics and cellulitis is a bacterial infection of the dermis and subcutaneous tissues underneath the skin and is the most common complication associated with lymphangiosarcoma. Thus, owing to the above factors the market is expected to hamper over the forecast period.

Segment Analysis

The global angiosarcoma treatment market is segmented based on type, treatment, end users, and region.

Immunotherapy from the Treatment Segment Accounted for Approximately 38.5% of the Global Angiosarcoma Treatment Market Share

The rising clinical trials of angiosarcoma globally have contributed to the growing demand for angiosarcoma treatment. Immunotherapy includes drugs that activate the immune system that modify the immune system cells to target tumor cells and monoclonal antibodies, checkpoint inhibitors, and vaccines are the common types of immunotherapies.

For instance, according to clinicalTrials.gov, on April 5, 2023, M.D. Anderson Cancer Center conducted a clinical trial on Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma. The main aim is to determine the safety, toxicity, and feasibility of delivering autologous dendritic cells (DCs) loaded with tumor lysate plus mRNA to patients with cutaneous head & neck angiosarcoma as adjuvant therapy. Thus, the above factors help to acceleratethe market growth.

Geographical Penetration

North America Accounted for Approximately 38.4% of the Market Share in 2022

North America has maintained a significant proportion of the angiosarcoma market in recent years, and this trend is anticipated to continue throughout the forecast period due to the factors such as an increase in healthcare expenditures, increasing research and developments, and technological advancements in angiosarcoma treatment.

For instance, according to the National Health Expenditure Account (NHEA), the total annual healthcare expenditure in the United States is increased by 2.7% to $4.3 trillion. Physician spending grew by an average of 3.8% per year while hospital services (4.5%) and clinical services (6.6%) had higher growth rates.

Competitive Landscape

The major global players in the market include Novartis AG,Bayer AG,Sanofi,Amgen Inc.,Eli Lilly and Company,Genentech Inc.,Janssen Pharmaceuticals, AbbVie Inc, Bausch Health, GlaxoSmithKline Plc.among others.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the angiosarcoma treatment market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in angiosarcoma treatment research. Clinical trials are vital for developing new treatments and improving outcomes in the angiosarcoma treatment market.

However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies. Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the angiosarcoma treatment market is expected to be moderately affected over the forecast period.

By Type
• Hemangiosarcoma
• Lymphangiosarcoma
• Parenchymal Angiosarcoma

By Treatment
• Surgery
• Radiotherapy
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Others

By End Users
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• In September 2020, during the ESMO Virtual Congress, data from the sarcoma cohort of the phase 2 basket study is presented and showed that pembrolizumab monotherapy prolonged progression-free survival (PFS) in selected rare sarcoma subtypes including epithelioid sarcoma, angiosarcoma, and chondrosarcoma.
• In December 2020, a new study led by clinician-scientists from the National Cancer Centre Singapore (NCCS) with collaborators from research institutions worldwide found that angiosarcomas have unique genomic and immune profiles which allow them to be classified into three different subtypes. With this new classification, patients can be treated using a personalized-medicine approach.

Why Purchase the Report?
• To visualize the global angiosarcoma treatment market segmentation based on the type, treatment, end users, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of globalangiosarcoma treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global angiosarcoma treatment market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies